< Back to latest news & events

Blogs

Update on the Precision Breeding Act 2023: details emerge of the new simplified regulatory pathway for gene edited plant and animal derived food and feed products

January 2025

The Genetic Technology (Precision Breeding) Act 2023 could come into force as early as spring 2025. It empowers the Food Standards Agency (FSA) to create a new simplified regulatory pathway for the marketing authorisation of precision bred plants and animals, and derived food and feed products. Here we review the latest policy developments which shed light on what this new regulatory pathway will look like for applicants.

As a brief recap, the Act applies to animals, plants and algae, which are considered “precision bred” if their genome is altered using modern biotechnology in a stable (heritable) way that could have occurred through traditional breeding. The FSA is granted powers under the Act to establish a simplified, proportionate, and science-based regulatory pathway for the marketing authorisation of Precision Bred Organisms and food and feed produced from Precision Bred Organisms in the UK.

The FSA is currently developing this new regulatory pathway, the so-called Precision Breeding Regulatory Framework. Their Delivery Plan and Policy Update (linked below) were both updated last month, providing us with the most recent details on the practicalities of this new regulatory pathway.

Under the new pathway, organisms will first need to be confirmed as having Precision Bred Organism status by the Department for Environment, Food & Rural Affairs (Defra). This process will confirm their equivalence to traditionally bred organisms, which are not subject to premarket approval. Defra’s decision may take up to about 3 months. Only then can an application for food or feed authorisation be submitted to the FSA.

The FSA will implement a two-tiered food or feed marketing authorisation process. Tier 1 applications will be granted marketing authorisation without the need for a bespoke risk assessment. Instead, they will follow a new “lighter-touch” audit and registration process which is “greatly simplified compared to other regulated products processes”. The FSA estimates that decisions on Tier 1 applications will take two months.

Tier 2 applications, by contrast, will require a bespoke risk assessment focusing on specific safety concerns in a process that is “closely aligned with existing regimes”. The estimated timeframe for Tier 2 application decisions is significantly longer, taking 12 to 24 months depending on complexity. This complexity will be assessed by the FSA based on the novelty and scientific and risk management complexity of the application.

Applicants will need to determine the applicable tier to their product through a triage process based on a set of food safety criteria concerning novelty, nutritional quality, allergenicity, toxicity and other safety concerns. Products that raise any safety concerns will require Tier 2 approval. These concerns will presumably inform the focus of the bespoke risk assessment involved in Tier 2 applications.

The FSA estimates to receive about 18 applications per year, divided equally between the two tiers.

In short, the FSA is setting up a simpler faster (2 month) Tier 1 application process for the food and feed marketing authorisation of Precision Bred Organisms, alongside a bespoke slower (1-2 year) Tier 2 application process to tackle specific safety concerns. Questions remain about the exact triage criteria that will decide the tier of an application, with detailed guidance for applicants expected to be released soon.

Follow our Agritech Thymes blog for further developments.

Further reading

https://www.food.gov.uk/board-papers/precision-breeding-delivery-plan

https://www.food.gov.uk/board-papers/policy-development-precision-breeding


This article was written by Trainee Patent Attorney Aron Ferenczi

Latest updates

Agritech Thymes: The Bite of Implied Consent: Lessons from the Pink Lady Case

Can the supply of a plant variety without clear and defined restrictions on its use be an implicit consent to commercialise it? This case centres on the evidence required to …

Read article

IAM Global Leaders 2026

HGF is proud to announce that we have 3 partners listed as an IAM Global Leader 2026. To qualify for inclusion in the IAM Global Leaders, individuals must be ranked …

Read article

The Bite of Implied Consent: Lessons from the Pink Lady Case

A recent European Union court decision considers the issue of implied consent to commercialise a plant variety, and whether the evidence meets the threshold of “serious doubts” of the validity …

Read article
Event - 5th November 2025

HGF are Gold Sponsors of IAM Live: Navigating the UPC 2025

We’re excited to share that HGF is a Gold Sponsor of IAM Live: Navigating the UPC 2025, taking place on the 5th November at the Marriott Opera Ambassador Hotel in …

Event details

HGF ranked band 1 in Chambers and Partners UK 2026

The Chambers and Partners UK 2026 Guide is now live and HGF has one again been highly ranked as a firm, with several recognised individuals across multiple regions. HGF is …

Read article

How France's investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Read article
Event - 14th October 2025

The Future of Protein Production Amsterdam 2025

HGF are proud to be sponsoring the Future of Protein Production Amsterdam 2025, the leading global event bringing together innovators across fermentation, cultivated and plant-based proteins. Date: 29-30th October 2025  …

Event details

A Turning Point for AI Patent Eligibility?

Director Squires Vacates PTAB § 101 Rejection in DeepMind Case In a notable early move as Under Secretary of Commerce and USPTO Director, John Squires has vacated a Patent Trial …

Read article